Salubris(SZ:002294) Xin Lang Cai Jing·2025-09-25 01:48Core Insights - On September 25, 2023, Shenzhen Xinlitai Pharmaceutical Co., Ltd. saw a stock price increase of 5.05%, reaching 63.28 CNY per share, with a trading volume of 313 million CNY and a turnover rate of 0.45%, resulting in a total market capitalization of 70.546 billion CNY [1] Company Overview - Shenzhen Xinlitai Pharmaceutical Co., Ltd. was established on November 3, 1998, and went public on September 10, 2009. The company is located at 37th Floor, Main Building, Green View Plaza, Chegongmiao, Shenzhen, Guangdong Province [1] - The company's main business involves the research, production, and sales of pharmaceuticals and medical devices. The revenue composition is as follows: formulations 81.69%, medical devices 8.54%, raw materials 7.17%, and others 2.59% [1] Fund Holdings - According to data from the top ten holdings of funds, Hongtu Innovation Fund has a significant position in Xinlitai, with its Hongtu Innovation Healthcare Stock Fund (010434) holding 615,300 shares, accounting for 9.94% of the fund's net value, making it the largest holding [2] - The Hongtu Innovation Healthcare Stock Fund was established on October 20, 2020, with a current size of 293 million CNY. Year-to-date returns are 55.78%, ranking 413 out of 4220 in its category, while the one-year return is 65.67%, ranking 1280 out of 3820 [2] - The fund manager, Liao Xinghao, has been in position for 3 years and 308 days, with total assets under management of 476 million CNY. The best fund return during his tenure is 66.47%, while the worst is 47.49% [2]